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ABSTRACT
Background: Reports of primary intraabdominal synovial
sarcomas are extremely rare.
Methods: A literature review using PubMed was per-
formed. A retrospective review of the one known case at
our institution was completed.
Results: Even the most experienced pathologists report
that synovial sarcomas can be very difficult to diagnose
correctly. One cytogenic abnormality that is common
(90%) and pathognomonic for synovial sarcoma is a
characteristic chromosomal translocation resulting in the
SYT/SSX fusion gene. Wide regional excision has been
performed for intraabdominal sarcoma, with improved
results. Our patient is more than 24 months with no
evidence of recurrent or metastatic disease.
Conclusions: The prognosis for patients with intraab-
dominal synovial sarcoma remains poor. However, wide
regional excision may allow for prolonged disease-free
survival.
Key Words: Synovial sarcoma, Small intestine, Wide
excision.
INTRODUCTION
Synovial sarcomas are rare, unique spindle cell tumors
and account for approximately 10% of all soft tissue tu-
mors. A review of the literature reveals that a majority of
such tumors are retroperitoneal and located in the pel-
vis.1–5 Fourteen cases of reported primary intraabdominal
synovial sarcoma involving the gastrointestinal tract have
been reported, and only 3 of the cases involved small
intestine, the mesentery, or the omentum.1–13
Historically, the term synovial sarcoma refers to morphol-
ogy that resembles developing synovium.8 Ironically, cur-
rent research shows that synovial sarcomas arise from
mesenchymal stem cells and not actual synovial tissues.14
Typically, they occur in periarticular locations, with a
greater propensity for the lower extremities. In the litera-
ture, there have been an increasing number of reports of
synovial sarcomas being found in various locations
throughout the body. The median age at diagnosis is 35,
and there is no predilection for either sex. Unlike other
soft tissue histologies, synovial sarcoma has no identifi-
able etiologic agent or genetic condition that predisposes
an individual to develop this malignancy.14
CASE REPORT
The patient is a 39-year-old female who presented to the
Tulane Medical Center surgery clinic for evaluation of pro-
gressively worsening right-sided abdominal pain. The pa-
tient had experienced dull pain intermittently for 7 years to
10 years. She had seen numerous physicians about her ab-
dominal pain without any identification of a cause. The
evaluation and treatment had included an exploratory lapa-
roscopy at another facility approximately 7 years earlier, but
no anatomic abnormalities or pathology was identified.
The patient’s abdominal pain had become more constant
and severe, causing her to seek another medical opinion.
On physical examination, the pain was reproducible with
palpation. The patient had minimal guarding but no re-
bound tenderness. The remainder of her physical exami-
nation was unremarkable.
A CT scan was ordered along with routine laboratory tests
(CBC, comprehensive metabolic panel). The CT showed a
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CASE REPORT4x4-cm thickened area of the distal small bowel (Figure 1).
The blood work was within normal limits. After we dis-
cussed the results of the evaluation with the patient, ex-
ploratory laparoscopy was scheduled.
During exploratory laparoscopy, a friable mass, 4cm to
5cm in diameter, was identified in the mid ileum. Resec-
tion of an 8-cm segment of small bowel and adjacent
mesentery that included the mass was performed. Frozen
sections of the proximal and distal margins were normal,
and an extracorporeal end-to-end hand sewn anastomosis
was performed. Postoperatively, the patient had an un-
complicated hospital course and was discharged home.
Initial pathologic assessment revealed a 4.5-cm mass
thought to be a gastrointestinal stromal tumor (GIST).
Further histopathologic analysis revealed a monophasic
synovial sarcoma (see ‘Histopathology’ below).
The definitive diagnosis of synovial sarcoma was proven
by the confirmation of a chromosomal translocation re-
sulting in an SYT/SSX fusion gene. With the confirmation
of synovial sarcoma, determination of appropriate fol-
low-up treatment was determined based on the history of
synovial sarcomas in general. Synovial sarcomas have the
propensity to spread along tissue planes and generally
have a poor prognosis. The treatment of choice for syno-
vial sarcoma in the extremities is wide surgical resection,
including all adjacent lymph nodes. Little data exist in the
literature regarding surgical treatment of intraabdominal
synovial sarcoma. Based on the natural history of synovial
sarcoma and known recommendations, we recom-
mended reoperation to complete a more extensive resec-
tion of the adjacent bowel and mesentery. The patient
decided to proceed with the second surgery during which
a 45-cm segment of small bowel including the adjacent
mesentery, lymphatic, and vascular supply was resected
to the root of the mesentery. The specimen was sent to
pathology for examination.
The specimen from the second surgery consisted of a
45-cm long segment of small bowel centered on the pre-
vious anastomotic site. A 1-cm mass was identified in the
mesentery adjacent to the previous anastomotic site. Per-
manent pathology diagnosed the mass as synovial sar-
coma, and perineural and vascular invasion were identi-
fied. Thirty-one lymph nodes were found and were
negative for malignancy.
At the time of writing, the patient has completed a 24-
month follow-up. She has no abdominal pain or other
symptoms, and her examination is unremarkable. Her
laboratory results are normal, and CT scans of the chest
and abdomen do not reveal any evidence of disease.
Histopathology
Synovial sarcoma typically presents as 1 of 2 histologic
subtypes: monophasic or biphasic. Monophasic synovial
sarcomas are entirely composed of ovoid-spindle mor-
phology. Biphasic subtypes are composed of both spindle
and epithelial components. A poorly differentiated histo-
logic subtype has also been described. This subtype is
composed of uniform, densely packed small ovoid blue
cells. A poorly differentiated subtype is rarely found in
isolation; however, up to 20% of synovial sarcomas con-
tain isolated areas.14
In this case, a white-tan mass measuring 4.5cm in its
greatest dimension was resected. The tumor involved the
submucosa and extended into the mesentery. Histopatho-
logically, the mass was composed of a densely cellular
monomorphic population of spindled cells with focally
whorled areas. No epithelial components were identified.
Nuclei were plump and hyperchromatic, and mitoses
ranged from 8 to 21 per 50/HPF, demonstrating a high-
grade morphology. Both Ki-67 and p53 immunoreactivity
were diffuse, confirming the high proliferation index. Fo-
cal areas of necrosis were identified. Additional immuno-
histochemistry revealed positive immunoreactivity to vi-
mentin, CD99, EMA, and bcl-2. The tumor was negative
for c-kit (CD117), a marker often suggestive of gastroin-
testinal stromal tumor (GIST). Additionally, it was negative
for smooth muscle actin, desmin, S100, AE1/AE3, CAM
5.2, CK7, CD34, and CEA. At this point, a differential
diagnosis of an uncommon form of c-kit negative GIST
versus monophasic synovial sarcoma was considered. Tis-
sue was sent for further studies, which revealed positive
immunoreactivity for transduction-like enhancer gene Figure 1. Abdominal CT scan–mass involving small intestine.
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ment that showed a break apart signal on chromosome
18q11.2, characteristic for t(X,18).
Terry et al15 evaluated TLE1 as a useful immunohisto-
chemical marker for the diagnosis of synovial sarcoma,
because it is positive in a majority of cases. Fluores-
cence in situ hybridization (FISH) for the t(X;18) SYT-
SSX fusion gene remains the gold standard and pro-
vides the most definitive diagnosis.16 In this case, these
studies confirmed the diagnosis of synovial sarcoma,
monophasic type.
DISCUSSION
The diagnosis of synovial sarcoma is becoming easier due
to advanced techniques with FISH and immunohisto-
chemical staining. Heide et al9 have suggested that pri-
mary intraabdominal synovial sarcomas are underdiag-
nosed and therefore believe that primary synovial
sarcoma should be included in the differential diagnosis of
all CD117 negative abdominal spindle cell tumors. The
fact that synovial sarcomas are CD117 negative is impor-
tant, because it does not allow for the use of imatinib in
chemotherapy. The use of immunohistochemical staining
Table 1.
Summary of Publications
Authors Year Location Sex Age Type Size (mm) Treatment Outcome
Helliwell 1995 Ileal mesentery M 46 Biphasic 90x70x70 ANED 9 mo
Chan 2004 Jejunum
Wang 2006 Omentum M 66 Biphasic 200x200x100 Subtotal gastrectomy,
resection of omentum, liver
segmentectomy
Died 2 mo after
operation
(recurrence)
Buiga 2007 Ascending
mesocolon
F 41 Monophasic 100x60 Colectomy Not mentioned
Heide 2008 Duodenum F 39 Monophasic 50x40 Duodenectomy Recurrence after
8m o
Makhlouf 2008 Gastric atrum-
body junction
F 67 Monophasic 8 Partial gastrectomy after
biopsy
ANED 12mo
Body M 49 Monophasic 20 Segmental resection DOD omental
metastases, 29
mo
Body F 68 Monophasic 20 Wedge resection ANED 22 mo
Body M 29 Monophasic 28 Partial gastrectomy ANED 224 mo
Antrum,
gastroduodenal
junction
F 54 Monophasic 30 Antrectomy/gastroduodenal
resection
Recent case
Lesser
curvature/body
F 58 Monophasic 30 Wedge resection ANED 21 mo
Fundus F 37 Monophasic 40 Partial gastrectomy A Local
recurrence
9.5cm, reexcised
DOC 48 mo
Distal fundus M 50 Monophasic 60 Resection, chemotherapy Alive with
recurrence 6 mo
Greater
curvature/body
M 42 Biphasic 80 Partial gastrectomy,
chemotherapy
DOD 25 mo
Fundus F 66 Monophasic 150 Gastrectomy, partial
esophagectomy
Lost to follow-up
aANEDalive, no evidence of disease; DODdied of disease; DOCdied of other causes.
JSLS (2010)14:421–425 423for TLE1 and the use of FISH for the SYT-SSX fusion genes
will improve the diagnosis and treatment of patients with
synovial sarcomas.12,15
The prognosis for intraabdominal synovial sarcoma is
poor. According to Fisher et al,1 average survival rates
were only 17 months with a high incidence of recurrence.
This series included both retroperitoneal and intraab-
dominal tumors. Previous reports document that all pa-
tients with primary retroperitoneal sarcomas died within a
time period of 7 to 24 months. Their death was due to
recurrence or extension, while no sarcoma metastasized
out of the abdomen. Reports of intraabdominal sarcomas
not involving the retroperitoneum sarcomas were inter-
estingly disease free in the period of follow-up (9 months
to 6 years).17 Due to the limited number of reported cases,
it is difficult to determine the actual survival rates for
intraabdominal synovial sarcomas.10,17 However, litera-
ture is extensive regarding synovial sarcoma in the ex-
tremities, with reported 5-year survival rates of 76% and
disease-free survival rates of 59%, suggesting that similar
modes of surgical treatment may be beneficial for intra-
abdominal tumors.18,19 The standard of care for synovial
sarcoma reported in the orthopedic literature is wide local
excision or amputation, with lymph node biopsy. Based
on the results for synovial sarcoma of the extremities,
surgical excision—with a wide margin—is the only cura-
tive therapy and offers the best outcome; however, the
application to intraabdominal cases is largely unstudied.
Until this report, intraabdominal cases have been treated
by excision of the tumor but not with a wide margin. For
example, the cases of gastric synovial sarcoma reported
by Makhlouf et al17 were treated primarily by gastrectomy,
without further surgery. Table 1 summarizes the treat-
ments and results of published cases of intraabdominal
synovial sarcoma.
Other treatment modalities including radiotherapy and
chemotherapy have been evaluated, but the results are
not as good as results with wide surgical excision. The
role of adjuvant radiation therapy for tumors 5cm has
been shown to reduce the rate of recurrence. Chemother-
apy with ifosfamide with mesna  doxorubicin for meta-
static disease has been studied, but conclusions are lim-
ited by the small sample sizes. In addition, therapy with
ifosfamide, nitrogen mustard, is itself an associated signif-
icant morbidity.
In making a treatment plan for the patient, one must take
into consideration the highly malignant nature of synovial
sarcoma. We believe that wide surgical resection of the
tumor and adjacent tissue is the best option, based on the
standard of treatment for synovial sarcomas in the extrem-
ity and the high rate of local recurrence and extension. To
the best of our knowledge, this is the first reported case
where a second wider resection was performed after the
diagnosis of synovial sarcoma. The fact that our second
surgical specimen revealed a 1-cm mass separate from the
original tumor with perineural and vascular invasion illus-
trates the need for wide resection. This surgical case
highlights the need for wide surgical resection but also
brings up an interesting question. Were past synovial
sarcoma cases labeled recurrence actually recurrence, or
undiagnosed extension with inadequate resection? In our
case, reoperation with wide surgical resection was chosen
to decrease the chance of recurrence and reduce morbid-
ity and mortality.
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